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Abstract
Background: Novel molecular and statistical methods are in rising demand for disease diagnosis and prognosis
with the help of recent advanced biotechnology. High-resolution mass spectrometry (MS) is one of those
biotechnologies that are highly promising to improve health outcome. Previous literatures have identified some
proteomics biomarkers that can distinguish healthy patients from cancer patients using MS data. In this paper, an
MS study is demonstrated which uses glycomics to identify ovarian cancer. Glycomics is the study of glycans and
glycoproteins. The glycans on the proteins may deviate between a cancer cell and a normal cell and may be visible
in the blood. High-resolution MS has been applied to measure relative abundances of potential glycan biomarkers
in human serum. Multiple potential glycan biomarkers are measured in MS spectra. With the objection of
maximizing the empirical area under the ROC curve (AUC), an analysis method was considered which combines
potential glycan biomarkers for the diagnosis of cancer.
Results: Maximizing the empirical AUC of glycomics MS data is a large-dimensional optimization problem. The
technical difficulty is that the empirical AUC function is not continuous. Instead, it is in fact an empirical 0–1 loss
function with a large number of linear predictors. An approach was investigated that regularizes the area under
the ROC curve while replacing the 0–1 loss function with a smooth surrogate function. The constrained threshold
gradient descent regularization algorithm was applied, where the regularization parameters were chosen by the
cross-validation method, and the confidence intervals of the regression parameters were estimated by the
bootstrap method. The method is called TGDR-AUC algorithm. The properties of the approach were studied
through a numerical simulation study, which incorporates the positive values of mass spectrometry data with the
correlations between measurements within person. The simulation proved asymptotic properties that estimated
AUC approaches the true AUC. Finally, mass spectrometry data of serum glycan for ovarian cancer diagnosis was
analyzed. The optimal combination based on TGDR-AUC algorithm yields plausible result and the detected
biomarkers are confirmed based on biological evidence.
Conclusion: The TGDR-AUC algorithm relaxes the normality and independence assumptions from previous
literatures. In addition to its flexibility and easy interpretability, the algorithm yields good performance in
combining potential biomarkers and is computationally feasible. Thus, the approach of TGDR-AUC is a plausible
algorithm to classify disease status on the basis of multiple biomarkers.
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Background
With rapidly developing biotechnology, the use of high-
throughput clinical laboratory data to detect disease con-
ditions and predict patients' outcomes is becoming a real-
ity for medical practice. These technologies include
microarray, mass spectrometry applied to proteomics,
and new imaging modalities, which have been engaged in
research on detecting clinical disease, predicting patients'
responses to different treatments and evaluating the prog-
nosis of patients with disease [1].
Among those new biotechnologies, mass spectrometry
(MS) is used increasingly for protein profiling in cancer
research. The basic goal is to predict cancer on the basis of
peptide/protein abundance from the MS data. Recent lit-
eratures on cancer classification using MS have identified
some potential protein biomarkers in serum to distin-
guish cancer from normal samples (Baggerly et al.[2],
Wagner et al.[3], Adam et al.[4]). However, sensitivity and
reproducibility remains as a major concern in making the
protein technology reliable [5].
As an alternative, glycomics is proposed as a new trend for
biomarker detection at the end of 20th century. Glycom-
ics is the study of glycans (oligosaccharides), and glyco-
proteins. Apweiler et al.[6] estimated that at least 50% of
human proteins are glycosylated. Since glycans play cru-
cial roles in cell communication and signalling events [7],
they may be implicated in cancer. Compared to potential
protein or peptide biomarkers, oligosaccharides are
highly sensitive to biochemical environment and are
more easily identified and quantified [8]. Therefore, in a
study conducted in this lab, clinical glycomics is used to
identify potential biomarkers for the early detection of
ovarian cancer.
Ovarian cancer is one of the most deadly types of cancer
among women [8]. Many investigators believe that early
detection of ovarian cancer would improve the patients'
survival. CA 125 is the only FDA approved biomarker for
the early detection of ovarian cancer. However, it has
unreasonably low sensitivity and specificity. For instance,
only 50% women with Stage I ovarian cancer will have an
elevated CA 125 and many benign conditions can cause
elevated levels [8].
One technique of profiling oligosaccharides into serum
was developed in this lab. The idea that glycoproteins
which are sloughed off cells may be detected in patients'
serum was utilized for this analysis. Serum samples were
analyzed by the high-resolution MS to assess the variation
of glycans in cancer patient sera compared to healthy
patient sera. MS data are high-dimensional. Figure 1
shows a typical mass spectrum. In this experiment, a sin-
gle spectrum contains 500,000 distinct mass-to-charge
values (which measure the ratio of mass to the charge of
glycans) and the corresponding relative intensities (which
measure relative abundances of glycans) in the serum
sample. It is desirable to use all informative glycans
because multiple biomarkers may allow improved sensi-
tivity and specificity of cancer detection [9].
A number of recent studies have implemented machine
learning algorithms to classify high-dimensional MS can-
cer data. Artificial neural networks (ANNs) were utilized
by Ball et al.[10], Lancashire et al.[11] and Mian et al.[12],
to discriminate different tumor states. Fushiki et al. [13]
explored the efficient learning algorithm AdaBoost to
extract potential biomarkers for classifying MS cancer
from control samples. Decision tree based ensemble
methods were proposed by Geurts et al.[14] to identify
biomarkers for inflammatory diseases. Other algorithms,
such as support vector machine (SVM) used by Xiong et
al.[15], random forest (RF) applied by Wu et al.[16] and
linear discriminant analysis (LDA) employed by Miketova
et al.[17] and Lilien et al.[18], were also studied. Compar-
isons among algorithms in a case study of ovarian cancer
classification were evaluated by Datta and DePadilla [19]
and Wu et al.[16]. All of the above studies aim to discover
the potential MS biomarkers that can distinguish one
group from another. However, for prognostic and diag-
nostic purposes, how to combine those MS biomarkers
and whether or not the combination is optimal are not
addressed in those studies. Thus, an objective of this
Typical Glycomic Mass Spectrum Figure 1
Typical Glycomic Mass Spectrum. A typical mass spec-
trometry glycomics spectra is plotted. The x-axis is m/z value 
and the y-axis is the corresponding intensity, which measures 
the relative abundance of glycans.BMC Bioinformatics 2007, 8:477 http://www.biomedcentral.com/1471-2105/8/477
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research is to consider a statistical method that combines
the high-dimensional MS measurements into a single
score to classify cancer status jointly with suitable preproc-
essing of the data.
There are several studies on combining biomarkers. Su
and Liu [20] studied the case where markers follow a mul-
tivariate normal distribution. They gave a closed form of
optimal solution to the linear parameters. Normality is
not suitable for mass spectrometry data because measure-
ments of relative abundance are always positive. Pepe and
Thompson [21] considered linearly combining two
biomarkers by optimizing the area under the ROC curve.
The method was developed only for low-dimensional sit-
uation. And it is not trivial to generalize the approach to
high-dimensional case. Ma and Huang [22] applied Pepe
and Thompson's idea of optimizing AUC to microarray
experiment. They used multivariate normal distribution
in the simulation study and assumed independence
between biomarkers, which is not true for mass spectrom-
etry data. In addition, they implemented the threshold
gradient algorithm, first proposed by Friedman and
Popescu [23], without correctly recognizing the regulari-
zation parameter. In this work, the question on how to
combine the high-dimensional mass spectrometry predic-
tors into a single score for the purpose of classification is
addressed. The performance of a classifier by maximizing
the area under the ROC curve for linearly combining the
biomarkers is evaluated. The technical difficulty of this
optimization problem is that the empirical AUC function
is not differentiable. The objective function is in fact an
empirical 0–1 loss function with a large number of linear
predictors, and it is well known that such optimization
problem is ill-imposed. An approach that regularizes the
area under the ROC curve while replacing the 0–1 loss
function with a sigmoid function was investigated. A con-
strained threshold gradient descent regularization algo-
rithm, which is first introduced by Friedman and Popescu
[23], to stabilize the estimates is applied. In Friedman and
Popescu, they demonstrated their algorithm in a quad-
ratic objective function. In this study, their objective func-
tion is replaced with the area under the ROC. A
simulation is also conducted on mass spectrometry data
under the case-control design that will generate joint dis-
tribution of diseased samples and normal samples to eval-
uate this algorithm.
The article is organized as the following. Simulation study
is described in the Testing Section which describes how
effective the proposed TGDR-AUC approach is. The
Implementation Section is for real mass spectrometry
ovarian cancer data analysis after a description of our pre-
processing method. TGDR-AUC method is applied to
low-dimensional and high-dimensional ovarian cancer
data. In the Conclusion and Discussion Section, it is con-
cluded that the TGDR-AUC algorithm is appropriate in
the analysis of mass spectrometry glycomic data. A
detailed description for TGDR-AUC algorithm is in
Method Section. The definition and properties of the ROC
curve are reviewed. The area under the ROC curve as the
objective function for maximizing the performance of the
classifier is proposed. Furthermore, several sigmoid func-
tions that replace the 0–1 loss function are introduced and
a simple comparison among the sigmoid functions is
shown. Threshold gradient direct regularization algo-
rithm is explained after selection of sigmoid function as
well as the detailed algorithm for parameter estimations.
Results
Testing
Testing of the TGDR-AUC algorithm was demonstrated
through a simulation study. Since the mass spectrometry
measures the relative abundance of molecules, the meas-
urement is always positive. Hence, a positive distribution
is a reasonable choice for data simulation. In contrast to
Ma and Huang [22], who simulated data under normal
distribution and assumed independence among biomark-
ers, exponential distribution was chosen to generate the
simulation data. Since a better classifier is desired, the
data used for simulation were chosen so that the true AUC
equals to 0.95. The simulation is generated as the follow-
ing:
￿ Denote X as normal patient, and m is the number of nor-
mal patients. Denote Y as the disease patient, and n is the
number of diseased patients. For simplicity, we choose m
= n. The dimension of the biomarkers is denoted as p.
￿ Simulate Xi as an exponential distribution with parame-
ter λ = 1, i = 1, ..., n.
￿ Generate a Bernoulli trial B(1, 0.95) for n times.
￿ The data for the diseased patients are generated as Yi = Xi
+ 1 when Bernoulli trial is 1; Yi = max{0, Xi - 1} when Ber-
noulli trail is 0.
The number of the replication was chosen to be 500. The
data is generated as joint distribution of X and Y. The true
probability is P(X <Y) = 0.95, no matter what the linear
combination β is. The goal of the simulation study is to
show that the maximizer of empirical AUC by TGDR reg-
ularization is in fact our targeted maximization problem
(4) (see Additional file 1, 2 for examples of simulated
data).
To study whether the ratio of p and n has any impact on
the results, the simulation cases are considered for the dif-
ferent combination pair of p and n as p/n → + ∞, p/n → c,
where c is a constant and p/n → 0. The p and n pairs areBMC Bioinformatics 2007, 8:477 http://www.biomedcentral.com/1471-2105/8/477
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(10,5),(10,10),(10,25),(10,50),(25,5),
(25,10),(25,25),(25,50) and
(50,5),(50,10),(50,25),(50,50). The data are partitioned
randomly into a training set of size n1 and a testing size of
n2  with  n1  +  n2  = 2n. Dudoit [24] suggested that
. The TGDR algorithm described in the
Method Section was applied to the simulated data and
summary statistics of estimated empirical AUC based on
500 simulated data sets are reported in Table 1.
The simulation conducted is for a relatively small sample
size and a small number of biomarkers. From Table 1, the
regularization of TGDR tends to overestimate the AUC
when p is less than n. As sample size increases, the esti-
mated AUC by regularization approximates the true AUC.
Furthermore, as sample size increases, the standard error
stabilizes to be around 0.03.
Table 1 gives a guideline on how to use the TGDR-AUC
algorithm for different situations. When a larger sample
size n than biomarker p is observed, the algorithm is trust-
worthy, in the sense that the estimated AUC approxi-
mated the true AUC and the best ratio for p/n is around 1/
5.0. However, when the number of biomarkers is much
larger than the sample size, it remains unclear whether the
TGDR-AUC algorithm tends to overestimate the AUC.
Implementation
Two real MS data sets are analyzed, one low-dimensional
and another high-dimensional real ovarian cancer data.
The low-dimensional data is preprocessed, and high-
dimensional data is the mass spectrometry raw data. So
high-dimensional data will be preprocessed first before it
is carried on any further analysis. The high-dimensional
data is a subset of the low-dimensional data because of
missing raw data files. The TGDR-AUC algorithm is
applied to both data sets for cancer diagnosis. All of the
programming were done in C and R (see Additional file 2,
3, 4 for algorithm codes).
Low-dimensional Ovarian Cancer Data Analysis
The data contained 73 patients, among which 24 were
healthy patients and 49 were ovarian cancer patients.
Total 14 glycan biomarkers were pre-selected for the low-
dimensional data set. The 3-fold cross-validation TGDR-
AUC algorithm was applied to select regularization
parameter λ and then select the optimal tuning parameter
τ. Using the determined λ and τ, the estimated empirical
AUC for the data was further obtained. The result is sum-
marized in the first column in Table 2. The estimated
empirical AUC was as high as 0.95, which indicates an
excellent cancer diagnosis for linear combing the 14
biomarkers. The ratio of biomarker number 14 to sample
size number 73 was less than 1/5.0, so the estimated
empirical AUC was trustworthy as suggested by the simu-
lation results. The 500 bootstrap data sets were performed
for given both λ and τ. The bootstrap standard error (SE)
was 0.00126. The 95% confident interval for AUC was
(0.9513,0.9560). The estimated coefficients of the 14
biomarkers are plotted in Figure 2. From the figure,
biomarkers number 3 and 8 had the highest coefficients,
suggesting the highest influence on the cancer diagnosis.
Biomarkers number 11 and 13 had smaller estimated val-
ues, indicating less importance than other biomarkers.
The low-dimensional data ROC based on the 14 peaks are
plotted in Figure 3.
High-dimensional Ovarian Cancer Data Analysis
In this section, the analysis starts from the raw ovarian
cancer data. The problem with the raw mass spectrometry
data is that the data is high-dimensional, so extracting
useful information is crucial. For this high-dimensional
data set, there were 19 normal patients and 21 cancer
patients. Each patient had three measurements, called
10%, 20% and 40% fractions, corresponding to different
sample extraction methods carried out prior to the mass
nn n 1
2
321 3 ~. ≈
Table 1: Simulation Study Result. Summary statistics of the simulation results of TGDR-AUC algorithm.
p n Bias Mean of Empirical AUC Median of AUC Standard Error
10 5 0.0088 0.9588 1 0.0857
10 10 0.01674 0.96674 1 0.0535
10 25 0.0087 0.9587 0.96 0.0375
10 50 0.0009 0.9509 0.9576 0.0300
25 5 0.0166 0.9666 1 0.0779
25 10 0.0226 0.9726 1 0.047
25 25 0.016 0.966 0.968 0.0338
25 50 0.007 0.957 0.96 0.0273
50 5 0.0172 0.9672 1 0.0795
50 10 0.028 0.978 1 0.0473
50 25 0.0218 0.9718 0.9808 0.0311
50 50 0.0086 0.9586 0.96 0.0268BMC Bioinformatics 2007, 8:477 http://www.biomedcentral.com/1471-2105/8/477
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spectrometry experiments. For each spectrum, the raw
data contained 500,000 data points. The mass spectrome-
ter's manufacturer(Varian FTMS Systems, Lake Forest, CA)
provided their software for peak-selection of individual
spectra from the 500,000 data points. The problem with
their peak-identification is that it is based on an individ-
ual spectrum, meaning that for any two spectra, peaks are
selected at different mass-to-charge values. Therefore, the
peaks are not consistent between samples and not trust-
worthy for cancer diagnosis. Before any data analysis is
performed, the preprocessing of the data is critical.
Preprocessing High-Dimensional Data
First, the peaks selected by the instrument's software for
the spectra were used. The selected-peaks were grouped
into a matrix, with each column corresponding to one
spectrum and each row corresponding to one distinct
mass-to-charge (m/z) value. If the spectrum did not have
the peak at the m/z value, a zero was replaced to indicate
missing value in the matrix. However, this resulted in
many zeros in the matrix. The corresponding raw data was
chosen to be substituted into the zero intensity. In this
way, much more similar information could be included as
the raw data.
However, the scale of raw data was not the same as the
corresponding selected-peaks data file. The ratio factor
between the raw and its corresponding selected-peaks file
needed to be estimated. The estimation of the ratio factor
was done as the following: find the nearest point in the
raw data to its corresponding selected-peaks data, defined
as the absolute distance between the corresponding m/z
values. Two cases may happen: if the nearest m/z value in
the raw data is unique, the ratio is calculated by the raw
data intensity to the selected-peaks data intensity at the
nearest value; if the nearest value is not unique, the ratio
is calculated by the averaged intensities of raw data at
those nearest values to the selected-peaks data intensity.
Low-dimensional Data ROC Figure 3
Low-dimensional Data ROC. Estimated ROC curve given 
the estimated optimal combination by TGDR-AUC algorithm 
of biomarkers for low-dimensional data.
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Table 2: Ovarian Cancer Data (with the bootstrap standard error in parenthesis). Implementation results of TGDR-AUC algorithm to 
MS ovarian cancer data.
Estimators Low-dimensional High-dimensional
Empirical AUC 0.953656(0.00126) 0.994987(0.0002527)
τ 10 . 1
λ 0.081559 0.000436
Low-dimensional Data Result Figure 2
Low-dimensional Data Result. Plot of estimated coeffi-
cients by TGDR-AUC algorithm of potential biomarkers for 
Low-dimensional data.
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For each file, the ratio was then averaged to give the
unique factor estimation.
Using the estimated ratio for each file, the intensities from
raw data could then be calculated to fill in the data matrix.
There, again, may be two scenarios: if the closest m/z in
raw data is unique to the selected-peaks data, then substi-
tute in the corresponding raw data intensity with the
adjustment by its ratio factor; if the closest m/z in raw data
is not unique, then substitute in the maximum intensities
of those closest m/z raw data to the corresponding col-
umn of the data matrix, with adjusting by its ratio factor.
This was chosen as the maximum intensity because we
wanted to include the strongest signal to be substituted in
the data matrix.
After imputing the data as above, the data matrix was
formed with each spectrum as one column of the matrix
and intensities at all same m/z values. Before any statisti-
cal analysis could be completed, each column of the data
matrix was further normalized by dividing total ion cur-
rent of the corresponding raw data intensities to make
sure the comparison of the spectrum would be made on
the same level. An arbitrary factor 100000 times the inten-
sities in the data matrix was to amplify the normalized
intensities to a reasonable magnitude. Because the data
variation was dependent on the mean, log transform was
carried out on the data matrix. An arbitrary 0.00000001
was added in the intensities to ensure valid log transfor-
mation. The 10%, 20% and 40% fractions were combined
by adding intensities up at each m/z value to group the
data into one patient as one column in the data matrix.
After appropriate preprocessing of normalization and log
transformation, the intensities for MS data are assumed to
approximately meet the t-test requirements. We then per-
formed a t-test to each m/z value on factor whether the
patient had cancer or not. The p-values of the tests were
recorded. The false discovery rate (FDR) by Benjamini and
Hochberg [25] was applied to the t-test p-values to adjust
to multi-test problem. Only adjusted p-values less than
0.05 were selected out to be potential biomarkers. As a
result, 1228 biomarkers were selected for the high-dimen-
sional data case.
High-dimensional Data analysis result
A 3-fold cross-validation of the TGDR-AUC algorithm was
applied to the data. The result is listed as the second col-
umn in Table 2. The estimated empirical AUC was almost
perfect, close to 1. The bootstrap method was applied to
estimate the empirical AUC confident interval for 1228
biomarkers. 500 bootstrap data sets were generated. The
bagged empirical AUC for the given optimal pair of λ and
τ was calculated from the bootstrap sample. The estimated
standard error was 0.0002527. The confident interval for
bootstrap was (0.9945, 0.9955). The high-dimensional
data had a small sample size compared to a large number
of biomarkers, which suggests that the estimated empiri-
cal AUC may be overestimated by the simulation.
The estimated coefficients were also of interest, and the
estimated coefficients are plotted in Figure 4. There were
139 biomarkers (more than 10% of total biomarkers) that
had zero coefficients. Only 63 biomarkers had larger than
0.01 estimated coefficients. The TGDR-AUC algorithm
provided a simultaneous dimension reduction technique
so that if the estimated coefficient was zero, the corre-
sponding biomarker did not have contribution to the
AUC optimization. In this case, the dimension was
reduced to 5% of the original dimension of 1228. McIn-
tosh and Pepe [26] mentioned in their work that the AUC
increases with the number of combined biomarkers.
However, this may not be true. To see this, only the 63
biomarkers that have larger estimated coefficients were
chosen and all the rest biomarkers coefficients were set to
be zero. The ROC using all estimated 1228 biomarkers
was compared to the ROC using only 63 biomarkers in
Figure 5. The ROC with 63 biomarkers had a higher AUC
value compared to AUC using all 1228 biomarkers.
Although there was earlier doubt about the empirical
AUC being optimistic, the resulting empirical AUC with
smaller biomarker numbers indicated that this was a valid
approach. Therefore, TGDR-AUC algorithm is a good clas-
sifier that provides the sufficiently unbiased AUC.
Selected biomarker lists were further compared to those of
peaks selected by their biochemical properties. Those 63
biomarkers were used because of their larger estimated
coefficients, which indicated their potential as cancer
biomarkers. Table 3 lists this result. The oligosaccharide
composition was from Hyun Joo An, et al.[8]. The
observed masses were also from that work for compari-
son. The biomarkers selected in that study matched well
to those in this analysis. All of these biomarkers had high
positive coefficients, which again suggest their potential
contribution to cancer identification. More peaks of
biomarkers are detected by more objective optimization
method of regularized AUC.
Three m/z values with large positive coefficients are plot-
ted in Figure 6. The m/z values 712.28, 915.43 were
selected because of their relative large estimated coeffi-
cients and m/z value 1442.72 was illustrated for a higher
mass range. The three plots correspond to the three areas.
Black is for healthy patients and red for cancer patients.
From the Figure 6, all of the areas visually showed larger
intensities for cancer patients than healthy patients. Larger
coefficients had visually larger differences between the
groups. The estimations were verified to make biological
sense.BMC Bioinformatics 2007, 8:477 http://www.biomedcentral.com/1471-2105/8/477
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Conclusion and Discussion
The key contribution of this work is that the optimal rules,
for purpose of classifying disease status on the basis of
multiple biomarkers, are based on the maximization of
the area under the ROC subjected to constrained thresh-
old gradient direct algorithm. The approach presented
here relaxes the normality assumption and the approach
of Pepe and Thompson [21] is generalized. The analysis is
applied to the high-dimensional mass spectrometry gly-
comics data. In contrast to Ma and Huang [22], the simu-
lation data is generated based on the joint distribution of
disease samples and control samples with non-normality
assumption, which is more appropriate for mass spec-
trometry data. This simulation is able to assess the differ-
ence between the maximization of the empirical AUC and
the target AUC. The simulation proves the asymptotic
properties that estimated TGDR-AUC approaches the true
AUC when the sample size is increasing compared to the
dimensionality of p biomarkers. When applied to the real
ovarian cancer data, the algorithm also provides the
Table 3: Comparisons of selected biomarkers between Hyun Joo An, et al. [8] and the TGDR-AUC algorithm. The biomarkers in Hyun 
Joo An, et al. [8] were selected based on their biochemical properties.
Observed Mass Oligosaccharide Composition Estimated linear coefficient
347.10 2Hex 0.138
388.14 1HexNAc:1Hex 0.462
509.17 3Hex 0.628
550.21 1HexNAc:2Hex 0.077
712.28 3Hex:1HexNAc 0.6299
772.31 2Hex:1HexNAc:1Hex 0.084
874.36 4Hex:1HexNAc 0.069
915.38 3Hex:2HexNAc 0.2724
975.43 2Hex:2HexNAc:1Hex 0.031
1077.47 4Hex:2HexNAc 0.204
1137.51 3Hex:2HexNAc:1Hex 0.0888
1280.62 4Hex:3HexNAc 0.0424
1442.72 5Hex:3HexNAc 0.0635
1502.74 4Hex:3HexNAc:1Hex 0.0449
High-dimensional Data Result Figure 4
High-dimensional Data Result. Plot of estimated coeffi-
cients by TGDR-AUC algorithm of potential biomarkers for 
high-dimensional data.
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High-dimensional Data ROC Figure 5
High-dimensional Data ROC. Estimated ROC curve 
given the estimated optimal combination by TGDR-AUC 
algorithm of biomarkers for high-dimensional data.
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1228 biomarkers,AUC=0.995
63 biomarkers,AUC=0.997BMC Bioinformatics 2007, 8:477 http://www.biomedcentral.com/1471-2105/8/477
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build-in dimension reduction technique. For the high-
dimensional ovarian cancer data, we can detect the 63
most important biomarkers among the total of 1228
biomarkers with simultaneously estimating the linear
combination coefficients. The selected 63 biomarkers
match very well with the 14 peaks pre-selected based on
biological evidence. The algorithm is a non-parametric
approach, very flexible and easy to interpret. The algo-
rithm is aimed to have optimal classification. The result-
ing AUC of the linear combination is plausible and
should be optimal among all other possible combina-
tions. The computation of TGDR-AUC is computational
feasible of high-dimensional data. This high-dimensional
analysis evaluates more than 1000 biomarkers in the algo-
rithm and essentially could consider more.
Although the result of simulation cannot guarantee the
estimated AUC comes close enough to the true AUC in
Three m/z value area to distinguish cancer from non-cancer Figure 6
Three m/z value area to distinguish cancer from non-cancer. Plot of m/z values areas which can discriminate ovarian 
cancer (red) from non-cancer (black). The upper left plot is for m/z value 712.28; the upper right plot is for m/z 915.38 and 
lower plot is for m/z 1442.72. The m/z values are visually larger for cancer patients. For quantification purpose, simple descrip-
tive statistics for the three areas are reported as the following: for m/z value 712.28, mean(standard deviation) of non-cancer 
samples are 4.506(3.181) and cancer samples are 10.633(3.615). The FDR-adjusted p-value for the comparison is 7.827e-07; for 
m/z value 915.38, mean(standard deviation) of non-cancer samples are 3.667(2.614) comparing to cancer samples 8.443(3.307). 
This results in FDR-adjusted p-value of 7.642e-06. The higher m/z 1442.72 has 2.958(2.435) for non-cancer samples of 
mean(standard deviation), while cancer samples are 7.275(3.1). The FDR-adjusted p-value for high mass area is 1.841e-05.BMC Bioinformatics 2007, 8:477 http://www.biomedcentral.com/1471-2105/8/477
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large p biomarker number for small sample size situation,
the algorithm still provides enough information in recog-
nizing potential biomarkers. Since the performance of
small dimension of biomarkers in the large sample size
scenario gives excellent overall result, iteratively combin-
ing the biomarkers in high-dimensional and reducing the
dimension of biomarker to some reasonable size is con-
sidered. With the reduced dimension, the biomarkers are
combined again using the TGDR-AUC algorithm. The
algorithm would continue until the ratio of number of
biomarker and the sample size are in the comfortable
zone suggested by our simulation. The TGDR-AUC algo-
rithm proves to be a promising algorithm and might be
recommended in combining mass spectrometry biomar-
ker analysis for cancer diagnosis.
Methods
ROC Curve
A case-control study is considered where the main out-
come is binary denoted as D, where D = 1 as the case and
D = 0 as the control. Denote the relative abundance of the
p glycomics Rp × 1 = (R1, ..., Rp)T. We consider the linear
combination score of the form
Lβ(R) = β'R = β1R1 + β2R2 + ... + βpRp (1)
where   is an unknown p-vector parame-
ter and R serves as the classification predictors. The classi-
fication rule is constructed by β'R. To be more specific, we
classify D = 1 if β'R ≥ c and D = 0 otherwise, for a cutoff
value  c. By varying the cutoff value c, we obtain the
Receiver Operating Characteristic(ROC) curve.
ROC is a graphical plot of the sensitivity and 1-specificity,
also known as true positive rate (TPR) and false positive
rate (FPR), respectively. The TPR and FPR are defined by
TPR(c) = Pr(β'R ≥ c|D = 1), (2)
FPR(c) = Pr(β'R ≥ c|D = 0) (3)
for any cutoff value c. By varying the discrimination value
of c, the TPR and FPR are plotted to generate the ROC
curve, which is a two-dimensional plot of FPR(c) vs
TPR(c) with -∞ ≤ c ≤ +∞. There is a balance between TPR
and FPR. A completely random predictor would give a
straight line at an angle of 45 degrees from the horizontal,
from bottom left to top right, because as the threshold is
raised, there would be equal numbers of true and false
positives. ROC above the no-discrimination line would be
preferred with better classification as the line closer to the
upper left-corner point (0,1).
The overall performance of the classifier can be evaluated
by the area under the ROC curve (AUC). Denote n as the
number of diseased samples, m as the number of normal
samples and p as the dimension of biomarkers. Denote Xi
= (Xi1, ..., Xip) as the i-th normal subject, and Yj = (Yj1, ...,
Yjp) as the j-th diseased subject, i = 1, ..., m, j = 1, ..., n. For
a given parameter β, the corresponding ROC curve is gen-
erated by linearly combining the p biomarkers for classi-
fier β'Y or β'X. It has been shown by Bamber [27] that the
theoretical area under the ROC curve is a probability
Pr(β'Y - β'X ≥ 0). To achieve the optimal performance, we
need to maximize
Statistically, the empirical AUC is given by
where the function Ψ(β; Xi, Yj) in (5) is defined as
The empirical AUC is the same as the form of Mann-Whit-
ney test statistics. The optimal estimator   is then
defined as the maximizer of AUC(β).
The Sigmoid Function
The main problem of the maximization (5) is that the
objective function is not continuous, and thus not differ-
entiable. The maximization is difficult to achieve and the
maximizer is not unique. To overcome the difficulty, a
smooth sigmoid function was chosen to approximate the
objective function. The sigmoid function is a monotoni-
cally increasing function with a parameter r > 0 and limx
→ -∞ Sr(x) = 0, and limx → +∞ Sr(x) = 1. There are many
choices of sigmoid functions, including:
The larger r is, the better the approximation will be. For a
given value r  = 10, Figure 7 shows the approximation
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result. The first function S1, r(x) approximates the best. The
first function S1, r(x) can be simply written as
Therefore, for the choice of sigmoid function, the first
function was used for further analysis. We now refer to the
estimator   as the maximizer of
where Y, X and index i, j are defined in (5).
Since the exponential part in sigmoid function may result
in unbounded situation when larger r is selected or the
data itself may be large, the exponential part was chosen
to be controlled by normalizing the data in the following
way: denote Zji = Yj - Xi, i = 1, ..., m, j = 1, ..., n. Z is a pair-
wise difference matrix between is the disease and normal
patients. We then normalize Z  as  Z/||Z||2, where
 and p is the dimension of Z.
Threshold Gradient Direct Regularization (TGDR)
The TGDR approach constructs a parameter path β(λ) in
parameter space that some of the points on that path are
close to the point β* in(6) representing the optimal solu-
tion. The best parameter path will be selected by k-fold
cross-validation technique. Consider now to minimize
where P(β) is the penalties. There are several candidate
penalty terms,  ,   and
P∞(β) = maxi = 1, ..., p βi, where p is the number of parame-
ters. We choose the quadratic penalty term
 because it is the most common one and
use this in our following analysis.
Let ν denotes the starting value on the path and Δν as the
increment on the path. To implement the algorithm, we
select Δν = 0.01. For any given r of the sigmoid function,
a threshold τ is varying between 0 and 1. τ was chosen in
the algorithm to be a vector {0,0.1,0.2,...,0.9,1}. The
TGDR algorithm performs the following iteration steps:
￿ Initialize βi = 0.01 and ν = 0, for i = 1, ..., p.
￿ Compute the negative gradient gi(ν) = -∂G(β; λ)/∂βi eval-
uatedat βi(ν). Denote gi(ν) as the i-th component of g(ν).
If maxi{|gi(ν)|} = 0, stop the iteration.
￿ Compute vector of fi(ν) as the i-th component of f(ν);
fi(ν) = I{|gi(ν)| ≥ τ·maxl|gl(ν)|, l = 1, ..., p}.
￿ Update βi(ν + Δν) = βi(ν) + Δν × gi(ν) × fi(ν). Replace by
ν + Δν.
￿ Repeat step 2–4 until β  converges, which means
. ε is a pre-select small number
and k is the number of iteration steps. We choose ε = 1 ×
10-8.
The tuning parameter or the threshold τ controls the dis-
tribution of estimator  . When τ = 0, the estimator β is
updated on every gradient and therefore the converged
estimator is close to ridge regression (RR); while τ = 1, the
estimated β is only updated on the maximum gradients,
and the result is roughly corresponding to LASSO (Least
Sx
rx
r 1
1
12
, ()
exp( )
. =
+−
ˆ β
ˆ (( ) ), ββ β ≡ ′ −
⎧
⎨
⎪
⎩ ⎪
⎫
⎬
⎪
⎭ ⎪ = = ∑ ∑ argmax
mn
SY X rj i
j
n
i
m
1
1 1
(6)
ZZ i i
p
2
2 2
1 =
= ∑
G
mn
SY X P rj i
j
n
i
m
(;) (( ) ) () βλ β λ β β =− ′ −+
⎧
⎨
⎪
⎩ ⎪
⎫
⎬
⎪
⎭ ⎪ = = ∑ ∑ argmin 1
1
1 1
, ,
(7)
P i i
p
1 1 () ββ =
= ∑ P i i
p
2
2
1 () ββ =
= ∑
P i i
p
2
2
1 () ββ =
= ∑
()
() ( ) ββε i
k
i
k
i
p +
= −≤ ∑
1 2
1
ˆ β
Sigmoid Function Approximation with r = 10 Figure 7
Sigmoid Function Approximation with r = 10. Several 
candidate sigmoid functions are plotted to approximate the 
indicator function.
−1.0 −0.5 0.0 0.5 1.0
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
sigmoid approximation with r=10
x
s
i
g
m
o
i
d
 
f
u
n
c
t
i
o
n
S1
S2
S3
indicatorBMC Bioinformatics 2007, 8:477 http://www.biomedcentral.com/1471-2105/8/477
Page 11 of 12
(page number not for citation purposes)
Absolute Shrinkage and Selection Operator, [28]). The τ
values in between 0 and 1 create the estimators more
diverse than RR, but less than LASSO.
Double Cross-Validation
The selection of the parameter path λ is determined by k-
fold cross-validation(CV). Since the empirical AUC is in
fact a nonparametric two-sample comparison test, a slight
variant of k-fold CV is considered and it is called double
k-fold CV for two samples. The n  number of diseased
patients Y is randomly split into roughly equal-sized K1
parts and m number of normal patients X into roughly
equal-sized K2 parts. Let k1 index which of {1, ..., n} is in
{1, ..., K1} groups, and k2 index which of {1, ..., m} is in
{1, ..., K2} groups. The cross-validation estimate of predic-
tion error is defined to be
where   is calculated by (7) when the k1(j) part
of Y and k2(i) part of X data are removed. The optimal λ*
is found by minimizing (8).
The function in (8) reduces the p-dimensional optimiza-
tion problem to be one-dimensional of minimizing λ.
The golden section search method [29] was implemented,
which does not require the calculation of the derivative, as
the optimization method to search for the minimal value
between 0 to a large number.
For any given τ in {0,0.1,0.2,...,0.9,1}, we run a double k-
fold cross-validation. Denote τl, l = 1, ..., 11 as the l-th
component in the vector {0,0.1,0.2,...,0.9,1}. After selec-
tion of regularized   estimator for given τl, l = 1, ..., 11,
the optimal   is chosen to be min{CV() ,   l = 1, ..., 11},
where CV(λ) is evaluated by substituting the regularized
 in (8). One may also adapt Stone's two-stage cross-val-
idation [30], but it will be computationally intensive.
Positive constraints
Because of the positive nature of the mass spectrometry
data, a positive constraint on the parameter β is reasona-
ble. The objective function (7) is minimized subjected to
the constraints βk ≥ 0 for k = 1, ..., p. Hence, the estimation
 will result in some exact zero coefficients when the
optimization hits the positive constraint boundary, which
means that the biomarker has no contribution to maxi-
mize the AUC.
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